Stacey R. Slingerland

Stacey R. Slingerland

Auto-generated profile, based on publicly available information

Stacey R. Slingerland

Catharina Heart Centre, Catharina Hospital , P.O. Box 1350, Eindhoven 5602 ZA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
JVJasper Vermeer
Jasper Vermeer
TVTineke Vinck
Tineke Vinck
BLBianca de Louw
Bianca de Louw
SSStacey Slingerland
Stacey Slingerland
MVMarcel Van 't Veer
Marcel Van 't Veer
LDLukas Dekker
Lukas Dekker
Progression of atrial fibrillation (AF) and outcomes of ablation therapy are strongly affected by modifiable risk factors. Although previous studies show beneficial effects of modifying single risk factors, there is lack of evidence from randomized controlled trials on the effects of integrated AF lifestyle programmes. The POP trial is designed to evaluate the clinical outcomes of a dedicated nurse-led AF lifestyle outpatient clinic in patients with symptomatic AF. This study is a prospective, 1:1 randomized, single centre, investigator-initiated clinical trial in 150 patients with paroxysmal or persistent AF referred for a first pulmonary vein isolation (PVI). Prior to the ablation, patients in the intervention group receive a personalized risk factor treatment programme in a specialized, protocolized, nurse-led outpatient clinic. Patient education and durable lifestyle management is promoted with an e-health platform. Patients in the control group receive standard care by cardiologists before ablation. The primary endpoint is the number of hospitalizations for re-ablation and cardioversion, with a follow-up of 12 months after ablation. Secondary endpoints include mortality, number of acute ischemic events, stroke or hospitalizations for heart failure, quality of life, number of ablations cancelled because of symptom reduction, and ablation success rate at 12 months. Determinants of patient and staff experience are explored and a cost-effectiveness analysis is included. The POP trial will help ascertain the efficacy and cost-effectiveness of an integrated technology-supported lifestyle therapy in patients with symptomatic AF. The trial is funded by the Netherlands Organisation for Health Research and Development [10070012010001]. Home sleep apnoea testing devices were provided by Itamar Medical, Ltd.ClinicalTrials.gov Identifier NCT05148338. Graphical abstract AF atrial fibrillation, OSA obstructive sleep apnoea, PFA pulsed field ablation, PVI pulmonary vein isolation.

18 July 2024 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
SSS. R. Slingerland
S. R. Slingerland
DSD. N. Schulz
D. N. Schulz
GSGijs van Steenbergen
Gijs van Steenbergen
MSMohamed Soliman-Hamad
Mohamed Soliman-Hamad
JKJ. M. H. Kisters
J. M. H. Kisters
DVD. van Veghel
D. van Veghel
Background: Type I and type II diabetes mellitus (DM) patients have a higher prevalence of cardiovascular diseases, as well as a higher mortality risk of cardiovascular diseases and interventions. This study provides an update on the impact of DM on clinical outcomes, including mortality, complications and reinterventions, using data on percutaneous and surgical cardiac interventions in the Netherlands. Methods: This is a retrospective, nearby nationwide study using real-world observational data registered by the Netherlands Heart Registration (NHR) between 2015 and 2020. Patients treated for combined or isolated coronary artery disease (CAD) and aortic valve disease (AVD) were studied. Bivariate analyses and multivariate logistic regression models were used to evaluate the association between DM and clinical outcomes both unadjusted and adjusted for baseline characteristics. Results: 241,360 patients underwent the following interventions; percutaneous coronary intervention(N = 177,556), coronary artery bypass grafting(N = 39,069), transcatheter aortic valve implantation(N = 11,819), aortic valve replacement(N = 8,028) and combined CABG and AVR(N = 4,888). The incidence of DM type I and II was 21.1%, 26.7%, 17.8%, 27.6% and 27% respectively. For all procedures, there are statistically significant differences between patients living with and without diabetes, adjusted for baseline characteristics, at the expense of patients with diabetes for 30-days mortality after PCI (OR = 1.68; p <.001); 120-days mortality after CABG (OR = 1.35; p <.001), AVR (OR = 1.5; p <.03) and CABG + AVR (OR = 1.42; p =.02); and 1-year mortality after CABG (OR = 1.43; p <.001), TAVI (OR = 1.21; p =.01) and PCI (OR = 1.68; p <.001). Conclusion: Patients with DM remain to have unfavourable outcomes compared to nondiabetic patients which calls for a critical reappraisal of existing care pathways aimed at diabetic patients within the cardiovascular field.

19 June 2025 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
SSSr Stacey Slingerland
Sr Stacey Slingerland
JBJlpm Maarten Van Den Broek
Jlpm Maarten Van Den Broek
DSDn Daniela Schulz
Dn Daniela Schulz
GSGijs van Steenbergen
Gijs van Steenbergen
LDLrc Lukas Dekker
Lrc Lukas Dekker
DVD Dennis van Veghel
D Dennis van Veghel
Background: Atrial fibrillation is increasingly prevalent and constitutes a severe economic and clinical burden. Pulmonary vein isolation (PVI) is an effective treatment. Evidence on the safety of same-day discharge (SDD) after PVI, instead of overnight stay (ONS), is limited. Methods and results: This retrospective study uses data from PVI’s performed between June 2018 and December 2020 in the Netherlands. Baseline characteristics, clinical outcome data, and healthcare utilization, extracted from two national databases, were compared between the implementation of an SDD protocol in a single center and a national benchmark where the majority is an ONS strategy. Descriptive and bivariate analyses were performed. We included data from 11,812 PVI’s,1360 in the SDD protocol group, and 10,452 for the ONS benchmark. The SDD protocol group performed 57.7% of PVI’s in SDD, while the benchmark performed 5.3% (p < 0.001). The SDD protocol group performed more cryoballoon PVI (90.8% vs. 39.2%, p < 0.001). There were no differences in bleeding (p = 0.830), thromboembolic (p = 0.893), vascular complications (p = 0.720), or cardiac tamponade (p = 0.634). Peri-procedural hospital stay was significantly shorter in the SDD protocol group (0.50 day vs. 1.52 days, p < 0.001), without a reallocation of health care to outpatient clinic (p = 0.230), emergency department (p = 0.132), or a higher rate of readmission (p = 0.092). Conclusion: The SDD protocol group with 57.7% SDD has similar complication rates and lower healthcare utilization, compared to the national ONS benchmark with 5.3% SDD, indicating that the SDD protocol is a safe and effective alternative for ONS in patients undergoing PVI. The implementation of an SDD protocol results suggests a potential reduction of nationwide healthcare utilization. Graphical

16 November 2023 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
SSStacey R. Slingerland
Stacey R. Slingerland
KBKonrad A.J. van Beek
Konrad A.J. van Beek
DSDaniela N. Schulz
Daniela N. Schulz
GSGijs van Steenbergen
Gijs van Steenbergen
TBTim Brouwer
Tim Brouwer
DVDennis van Veghel
Dennis van Veghel
This study evaluates clinical outcomes after implementing a liberal post-dilatation strategy during PCI. Post-dilatation after percutaneous coronary intervention (PCI) is performed to achieve optimal stent expansion and reduce complications. However, its prognostic effects are unclear and conflicting. This study is a pre-post intervention analysis of two cohorts, before (2015-2017) and after (2018-2020) implementation of a liberal post-dilatation strategy. The primary endpoint consisted of major adverse cardiovascular events (MACE) at 30-days. Secondary endpoints consisted of the individual components of the primary endpoint as well as 1 year mortality and target vessel revascularization. A total of 10,153 patients were included; 5,383 in the pre-cohort and 4,770 in the post-cohort. The 30-day MACE was 5.00% in the pre-cohort and 4.09% in the post-cohort (p=0.008; OR 0.75 (CI 0.61-0.93)). There was a significant difference between the pre- and post-cohort in 30-day mortality, respectively 2.91% and 2.25% (p=.01; OR 0.70 (CI 0.53-0.93)), and MI at 30 days, 1.17% versus 0.59% (p=.003; OR 0.49 (CI 0.31-0.78)). At 1 year, there was a significant difference in mortality between the pre-cohort, 5.84%, and post-cohort, 5.19% (p=.02; OR 0.79 (CI 0.66-0.96)). A liberal post-dilatation strategy after PCI was associated with a significant decrease in 30-day MACE, 30-day MI, 30-day mortality and 1-year mortality. Future studies are warranted to validate the causality between post-dilatation and improvement of clinical outcomes.

1 September 2023 in International Journal of Healthcare Management
Verified
Journal Article
Closed access
SSS. R. Slingerland
S. R. Slingerland
DSD. N. Schulz
D. N. Schulz
LDL. Dekker
L. Dekker
PWP. van der Wees
P. van der Wees
NMN. J. M. van der Meer
N. J. M. van der Meer
DVD. van Veghel
D. van Veghel

1 December 2023 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
SSStacey R. Slingerland
Stacey R. Slingerland
MKMileen R. D. van de Kar
Mileen R. D. van de Kar
GSGijs J. van Steenbergen
Gijs J. van Steenbergen
DSDaniela N. Schulz
Daniela N. Schulz
LDLukas Dekker
Lukas Dekker
DVDennis van Veghel
Dennis van Veghel
Measuring costs and outcomes: what are suitable models while implementing value-based healthcare in thoracic surgery?